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A B S T R A C T
Cryptosporidium is a genus of single celled parasites capable of infecting a wide range of animals including humans. Cryptosporidium species are members of the
phylum apicomplexa, which includes well-known genera such as Plasmodium and Toxoplasma. Cryptosporidium parasites cause a severe gastro-intestinal disease
known as cryptosporidiosis. They are one of the most common causes of childhood diarrhoea worldwide, and infection can have prolonged detrimental eﬀects on the
development of children, but also can be life threatening to HIV/AIDS patients and transplant recipients. A variety of hosts can act as reservoirs, and Cryptosporidium
can persist in the environment for prolonged times as oocysts. While there has been substantial interest in these parasites, there is very little progress in terms of
treatment development and understanding the majority of the life cycle of this unusual organism. In this review, we will provide an overview on the existing
knowledge of the biology of the parasite and the current progress in developing in vitro cultivation systems. We will then describe a synopsis of current and next
generation approaches that could spearhead further research in combating the parasite.
Organisms comprising the genus Cryptosporidium ssp. were ﬁrst
identiﬁed by Tyzzer in 1907, who discovered Cryptosporidium muris in
the gastric glands of laboratory mice, but it was nearly 70 years before
Cryptosporidium spp. were identiﬁed as pathogens in humans (Nime
et al., 1976). In the 1980s, when AIDS was becoming more widespread,
it also became apparent that Cryptosporidium was prevalent among the
immunocompromised (Navin and Hardy, 1987). Since then, Cryptos-
poridium species have been identiﬁed as pathogens in humans, live-
stock, domestic pets and wild animals. The organisms are frequently
found in the gastrointestinal tract (Noordeen et al., 2002); however, the
precise location varies between species. Cryptosporidiosis usually pre-
sents as acute, non-bloody watery diarrhoea, but symptoms can include
nausea, vomiting and fever, among others (DuPont et al., 1995;
Chappell et al., 2006, 2011). While the disease is self-limiting in
otherwise healthy adults (DuPont et al., 1995; Chappell et al., 2006,
2011), the infection can be chronic, and fatal, in the im-
munocompromised humans (Weisburger et al., 1979) and young chil-
dren (Checkley et al., 2015) and animals (Pozio et al., 1997; Matsuura
et al., 2017). In addition, children can experience nutrient malabsorp-
tion and growth retardation when infection becomes chronic, even if no
symptoms are present (Tumwine et al., 2003; Bushen et al., 2007).
There is only one FDA-approved drug treatment for cryptosporidiosis,
nitazoxanide, which resolves diarrhoea after three or four days of
treatment in most immunocompetent individuals (Rossignol et al.,
2001; Amadi et al., 2002), but shows little eﬃcacy in young children
and immunocompromised individuals such as HIV/AIDS patients
(Amadi et al., 2002). Despite the worldwide prevalence of Cryptospor-
idium, there remain a number of unanswered questions regarding its
complex and multi-staged life cycle, in particular the molecular signals,
which determine progression through the various stages and the precise
mechanism of pathogenicity. A major factor preventing further under-
standing is still the lack of reliable, prolonged, in vitro models, which
can accurately reproduce the in vivo life cycle (Hijjawi, 2010). This
review will explore the cell biology of Cryptosporidium as well as the
current progress in in vitro culture and ‘omics investigations, before
exploring the future challenges of cryptosporidiosis.
1. Cryptosporidium: endogenous growth and life cycle
Cryptosporidium is widely considered to be an intracellular parasite,
and occupies an intracellular, but extra-cytoplasmic vacuole within the
host (Beyer et al., 2000; Petry, 2004; O'Hara and Chen, 2011). The life
cycle consists of numerous stages, and is usually divided into an initial,
asexual portion followed by the sexual stages, outlined in Fig. 1.
Cryptosporidium species are monoxenous, completing their entire life
cycle within a single host. Transmission occurs by ingestion of oocysts.
C. parvum, C. meleagridis and C. hominis oocysts are small, circular
bodies measuring 3–6 μm in diameter. Within the oocyst are four
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sporozoites measuring 2 μm×0.8 μm. Thick walled C. parvum oocysts
are extremely hardy and are resistant to many common disinfection
methods (Barbee et al., 1999). C. hominis oocysts seem to share similar
sensitivity to UV radiation, exhibiting 90% inactivation at 3mJ/cm2 UV
(Johnson et al., 2005). C. parvum oocysts stored between 0 and 20 °C
are infectious for several days (Fayer and Nerad, 1996) and, in some
cases up to 24 weeks (Fayer et al., 1998; Noordeen et al., 2002). In-
activation has been reported to be achieved by heating to 55 °C, and
boiling for 5min being adequate for inactivation (Fujino et al., 2002).
The highly resistant nature of the oocysts has been attributed to a
complex lattice structure (Harris and Petry, 1999), a surface glycocalyx
layer (Liu et al., 2010), carbohydrates, fatty acids and aliphatic hy-
drocarbons, hydrophobic proteins and an inner glycoprotein layer
(Jenkins et al., 2010). Transcriptomic analysis has revealed that oocysts
are highly active in protein synthesis and translation, along with pos-
sessing an active proteasome, and ubiquitin machinery (Zhang et al.,
2012). As C. parvum lacks all de novo nutrient synthesis genes and oo-
cysts become less infectious with age (Slifko et al., 1997), it is likely
that the parasite relies on protein recycling and its own reserves of
amylopectin to survive shifts in environmental conditions (Fayer, 1994;
Zhang et al., 2012). Cryptosporidium oocysts continued persistence in
the environment, combined with high shedding; e.g. 6× 1011 oocysts
during the ﬁrst year of life in C. parvum infected calves (Uga et al.,
2000) show the potential health threat of these organisms.
Ingestion of an oocyst causes a process known as excystation, ex-
pansion of a “suture” (opening in the oocyst wall) and release of four
motile sporozoites (Reduker et al., 1985a, 1985b). Sporozoites exhibit
gliding motility (Forney et al., 1998; Wetzel et al., 2005). In vitro at-
tachment and invasion occurs preferentially at 37 °C and at a pH of
7.4–7.6 (Chen et al., 1998; Huang et al., 2004), which are the condi-
tions of the distal ileum (Evans et al., 1988), where infection is ob-
served frequently. The sporozoite attaches to the plasma membrane of a
host cell and is then enveloped (Chen et al., 1998), followed by trans-
formation into a replicative trophozoite. Notable morphology changes
include the parasite becoming rounded and enlargement of the nucleus
(Bonnin et al., 1999; Beyer et al., 2000). Internalisation of the parasite
recruits vacuoles to the infected location, causing fusion and formation
of the parasitophorous vacuole (Huang et al., 2004). The transforma-
tion from invasive sporozoite to replicative trophozoite involves both
host and parasite derived factors (O'Hara and Chen, 2011). Glycopro-
teins present in sera, unidentiﬁed factors secreted by host cells and Gal-
GalNAc are all capable of inducing transformation into trophozoites
(Edwinson et al., 2016).
Trophozoite development is accompanied by the formation of the
‘feeder organelle’, a tube or tunnel which connects the parasite to the
host cell cytoplasm (Bonnin et al., 1999; Beyer et al., 2000; Huang
Fig. 1. Outline of the Cryptosporidium parvum life cycle [Adapted and modiﬁed from (Thompson et al., 2005)].
Ingested oocysts release sporozoites, which invade the ileum, developing into trophozoites and type I meronts, containing type I merozoites. Released type I
Merozoites can become trophozoites themselves or develop into type II meronts, which release type II merozoites, these develop into undiﬀerentiated gamonts.
Gamonts diﬀerentiate into macrogamonts or microgamonts, the latter produces microgametes, which fertilise macrogamonts. Sporulation occurs within the host,
releasing thick walled oocysts into the environment and thin walled oocysts, which auto-infect the same host organism.
Fig. 2. Organelles in C. parvum infection.
Transmission Electron Microscopy (TEM)
images showing the presence of a feeder orga-
nelle and mitochondrial-related organelles that
are formed within the parasite infecting COLO-
680N cells.
a. TEM image showing the formation of the
feeder organelle (fo), which anchors the main
body of the parasite to the peripheral of the
parasitophorous vacuole (pv). b. TEM image
demonstrating a clearly identiﬁable double
membrane structure of the mitosome within a
merozoite form of C. parvum. c. TEM image
showing numerous organelles within the sporozoite that has recently invaded a host cell. The electron dense structure that can be seen is the crystalloid body (cb).
The nucleus (nuc) and the mitosome (ms) can also be seen in this image.
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et al., 2004; Umemiya et al., 2005) (Fig. 2a). The feeder organelle has
been hypothesised as a mechanism of myzocytosis engaged in by other
gregarines, however no studies have shown transfer of host cytoplasm
to the parasite. The ATP binding cassette protein CpABC-1 is localised
to the host-parasite interface (Perkins et al., 1999; Zapata et al., 2002)
and likely confers selective nutrient uptake and/or metabolite expul-
sion. Beyer and colleagues demonstrated that replicative stages remain
intracellular, but extracytoplasmic in rat ileal cells (Beyer et al., 2000).
However, the parasite can also be found within the cytoplasm of in-
traepithelial macrophages in vivo. The life cycle progresses through
rounds of asexual merogony followed by fertilisation of gamonts, de-
velopment of zygotes and oocyst production. Trophozoites divide by
merogony to generate a type I meront containing six to eight type I
merozoites, which when released continue this cycle by developing into
trophozoites upon invasion.
At some stage, certain type I merozoites will develop into type II
meronts, which contain four type II merozoites (Fig. 1). This starts the
sexual stage of multiplication, as these merozoites develop into un-
diﬀerentiated gametes upon cell invasion, and will then develop into
macrogamonts or microgamonts, the latter of which produces micro-
gametes. The gametes fertilise the macrogamont and form a zygote,
which develops into one of two types of oocyst; the thin walled, which
will excyst and continue the replication cycle within the same host
(termed auto-infection), and/or the thick walled, which are shed into
the environment (Thompson et al., 2005). Scanning electron micro-
scopy using an in vitro cell infection (Human ileocecal adenocarcinoma-
HCT8; see below) has given a rough timeline of life cycle progression,
with trophozoite development occurring after 24 h of infection, type II
merozoites appearing after 48 h of infection and gametes being found
after 96 h (Borowski et al., 2010). Several recent studies have suggested
that there may be extracellular development (Rosales et al., 1993;
Hijjawi et al., 2002, 2004, 2010; Yang et al., 2015; Aldeyarbi and
Karanis, 2016a, 2016b, 2016c), and that sexual stages can divide by
binary ﬁssion (Borowski et al., 2010). Many of these reports show
stages bearing little structural similarity however, and have been
claimed as being a contamination (Woods and Upton, 2007), while
others have seen structural similarities between what groups have
termed ‘trophozoites’ in host cell free culture and aged, non-viable
sporozoites (Petry et al., 2009). Developing in vitro culture methods and
higher resolution microscopy techniques, which can support and vi-
sualise the parasite for more than two weeks is key to understanding the
life cycle and the roles extracellular stages play.
Due to the aforementioned observations, in many pre- and early-
millennium publications, Cryptosporidium was referred to as an in-
tracellular/extra-cytoplasmic parasite (Lingelbach and Joiner, 1998;
Capet et al., 1999; Elliott and Clark, 2000; Arrowood, 2002). However,
recent publications have begun using the term ‘epicellular’ to describe
C. parvum (Thompson et al., 2005; Valigurova et al., 2008; Clode et al.,
2015). This is a misleading use of the term, as epicellular pathogens by
deﬁnition associate with host membrane, but remain outside of the
boundaries of the host cell. During infection, the parasite, however,
interacts with host cell membrane, causing the cell to attempt to engulf
Cryptosporidium in membrane material (Elliott and Clark, 2000). As a
result, a parasitophorous vacuole forms around the extracellular life
cycle stage (either sporozoite or merozoites). The end result is the en-
capsulation of the parasite in a host-membrane derived vacuole that
does not fully enter the host cytoplasm, instead occupying an inter-
membranous region of the phospholipid bilayer. The boundaries of a
cell can be deﬁned by the outer most aspect of the phospholipid bilayer.
Anything within that boundary is intracellular and anything associating
with, however closely, but remaining outside is epicellular. Giardia
lamblia is one such epicellular parasite, utilising a concave surface ar-
chitecture to ‘suction cup’ onto host cells. By this deﬁnition, however,
Cryptosporidium is now within the borders of the host cell and is thus
“intracellular” and not “epicellular”. Most likely this observation is a
result of diﬀerential resolution in ﬁeld emission scanning electron
microscopy images, and newly advanced microscopy techniques, in-
cluding atomic force microscopy (AFM), might be able to resolve con-
troversy. Whilst at ﬁrst glance the images present clearly distinguish-
able host and parasite, many confocal and electron microscopy images
show that this is not the case as such an attachment would not have the
eﬀect on host nuclear envelope previously observed (Lingelbach and
Joiner, 1998; Miller et al., 2018a).
Cryptosporidium parasites have a remarkably streamlined metabo-
lism and reduced biosynthetic pathways (Abrahamsen et al., 2004).
Cryptosporidium species, speciﬁcally C. parvum and C. hominis, lack ca-
nonical mitochondria, instead having remnant ones, so called mito-
somes. These are small (around 100 nm across), circular, double
membrane bound structures (Riordan et al., 2003; Keithly et al., 2005),
which appear to be functionally reduced mitochondria (Fig. 2b and c)
that lack ATP synthesising capability and their own (mitochondrial)
genome (Abrahamsen et al., 2004; Hjort et al., 2010; Richardson et al.,
2015). However, components of a biochemical pathway (named Iron/
Sulpur Cluster assembly; ISC) have been recenty localised in C. parvum
mitosome, suggesting a functional role of this organelle (Miller et al.,
2018b). Other organelles common to apicomplexans, including rhop-
tries, dense granules and micronemes, are found in the invasive spor-
ozoite and merozoite stages (Petry, 2004). Also visible are the polar
rings, which localise to the apical end of the parasite (Petry, 2004).
Intracellular stages generally show a loss of the majority of the orga-
nelles seen in invasive stages, including the micronemes, rhoptries and
dense granules (Beyer et al., 2000). Notable are the presence of dense
granules containing amylopectin, ribosomes, a Golgi apparatus, and an
endoplasmic reticulum (Keithly et al., 2005).
In light of a collection of morphological and phylogenetic simila-
rities, Cryptosporidium has been reclassiﬁed from a coccidian to a gre-
garine (Ryan et al., 2016). Key similarities supporting this new Cryp-
tosporidium/gregarine lineage (Liu et al., 2016; Ryan et al., 2016)
include completing host-free life cycles, exhibiting large extracellular
gamonts, pairing reproductively end to end (syzygy), and changing cell
architecture to adapt to diverse environments eg. bioﬁlms, coelom,
intestines, soil, and water (Ryan et al., 2016). Other evidence to support
this alteration includes the lack of an apicoplast (a remnant plastid
present in many other apicomplexans, including Plasmodium and Tox-
oplasma), the ability to complete its life cycle in the absence of a host
cell in vitro (Hijjawi et al., 2004, 2010; Koh et al., 2013, 2014; Aldeyarbi
and Karanis, 2016a), and its unique intracellular but extra-cytoplasmic
niche (Borowski et al., 2010). It will be necessary for future studies to
focus on ultrastructural data in combination with ‘omics (see below)
approaches to elucidate further the phylogenetic relationship between
Cryptosporidium and gregarines, which will allow better understanding
of both the nature of the parasites’ oocysts but also their infection
strategies.
2. Cryptosporidium culturing
The lack of a reproducible culture method capable of supporting the
parasite life cycle long term (Hijjawi, 2010; Ryan and Hijjawi, 2015;
Karanis, 2017) is a major barrier that restricts a greater understanding
of this organism. One key process in C. parvum culture is the excystation
protocol used to prepare oocysts for infection. Numerous laboratories
use diﬀering excystation protocols, with the number of excysted spor-
ozoites vs the number of oocysts being used as a measure of viability. It
has recently been established that the methods described by Rasmussen
et al. provides the highest rate of excystation (Pecková et al., 2016).
Another one is the use of primary cell lines and stem cells can provide
more accurate in vitro models of intestinal infection compared to es-
tablished epithelial cell lines, allowing higher yields of C. parvum ex-
tracellular stages. One study has demonstrated that non-carcinoma
epithelial cells of the small intestine show similar levels of infection to
Madin-Darby Bovine Kidney (MDBK) epithelial cells in terms of per-
centages of infected cells and an average of just below six infections per
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Table 1
Summary of cell lines reported as supporting C. parvum replication. Where multiple cell lines are listed, subsequent data refers to those in bold.
Cell Line/Type Oocyst Source Media Time Maintained Life Cycle Reference(s)
Chorioallantoic membrane of chicken embryos
(Hubbard broiler and White Leghorn
breed)
Naturally infected calf, infected AIDS
patient
N/A 8 days Complete life cycle Current and Long (1983)
Human foetal lung, Porcine kidney, Primary
chicken kidney
AIDS patient Minimal Essential Media with Earle's Salts, 2% FBS 7 days Complete life cycle Current and Haynes (1984)
HT29.74, Clone of colorectal cell line HT29 AIDS patient RPMI-1640, 10% FBS, 24mM sodium bicarbonate, 1mM sodium
pyruvate, 20mM HEPES (for undiﬀerentiated cells), Leibovitz L-
15 medium containing 5mM galactose, 6mM pyruvate, 1mM L-
glutamine, 20mM HEPES, antibiotics, 10% dialyzed fetal calf
serum (for diﬀerentiated cells)
13 days, rapid loss of
reinfection after 5 days
Asexual stages only Flanigan et al. (1991)
Mouse peritoneal macrophages Naturally infected calves RPMI-1640, 10% inactivated FBS 3 days Asexual, few
instances of gamonts
or oocysts
Martinez et al. (1992)
RL95-2, derived from human endometrial
carcinoma
Experimentally infected calves Dulbecco's modiﬁed Eagle's medium and Ham's F12 medium (1:1
ratio), 10% FBS, 10mM HEPES, 5 μg bovine insulin, 2% NaHCO3
(w/v)
4 days Complete life cycle (Rasmussen et al., 1993)
Madin-Darby canine kidney (MDCK) Infected calves Minimal Essential Media, 10% FBS 5 days Complete life cycle Rosales et al. (1993)
HRT-18 (Human rectal tumour) Experimentally infected calves RPMI-1640, 10% Inactivated FBS 6 days Asexual stages only (Woodmansee and
Joachim, 1983)
Caco-2 (Colorectal adenocarcinoma) Experimentally infected goats and
lambs, AIDS patient with persistent
cryptosporidiosis
N/A 5 days Complete life cycle (Buraud et al., 1991)
Madin-Darby bovine kidney (MDBK) Naturally infected calves (Villacorta
et al., 1996, Upton et al., 1994a,b)
Minimal Essential Media, 26mM NaHCO3, 4% FBS (Villacorta),
RPMI-1640 with L-glutamine, 10% FBS, 26mM NaHCO3, 15mM
HEPES (Upton)
3 days Complete life cycle (Upton et al., 1994a,b;
Villacorta et al., 1996)
BALB-3T3, BT-549, Hs700t, HT-1080, RL95-2,
HCT-8 (Colorectal adenocarcinoma)
Infected cows RPMI-1640 with L-glutamine, 10% FBS 3 days Not described (Upton et al., 1994a,b)
MRC-5 (lung ﬁbroblast) Clinical isolate Medium 199, Earles salts; essential amino acids, L-glutamine,
0.075% w/v sodium bicarbonate, 10% FBS
5 days Not described (Dawson et al., 2004)
BS-C-1 (African green monkey kidney cells) Infected calves Minimal Essential Media, 2 mM L-glutamine, 10% FBS 3 days Complete life cycle (Qi Deng and Cliver, 1998)












cell, nearly double the infections per cell of MDBK cells (Varughese
et al., 2014). In another study, C. parvum infection was maintained for
120 h using primary human intestinal epithelial cells (Castellanos-
Gonzalez et al., 2008), but the short life span and limited availability of
primary cells (compared with immortalised cell lines) have prevented
wider adoption of this method. Continuous cell lines are limited in their
ability to support the parasites life cycle completely and to support
continuous development, which tends to plateau after a week in culture
(Current and Haynes, 1984; Flanigan et al., 1991; Martinez et al., 1992;
Rosales et al., 1993; Upton et al., 1994a; Villacorta et al., 1996). Thus,
prolonged development requires host cells that could support the
complete life cycle and produce a high yield of both oocyst types to
propagate new infections and to continue existing infective cycles.
The ﬁrst in vitro culture system of C. parvum utilised endoderm cells
of the chorioallantoic membrane of chicken embryos, in which C.
parvum completed its life cycle between three and eight days (Current
and Long, 1983). Substantial developments have been made in cell
culture since, utilising several cell types, summarised in Table 1. HCT-8
has been used for most work on C. parvum (Hijjawi, 2010; Ryan and
Hijjawi, 2015; Karanis, 2017). It has been found that the level of HCT-8
infection can be increased with medium supplementation (Upton et al.,
1995). Addition of ascorbic acid, para-aminobenzoic acid, folic acid and
sodium pantothenate to RPMI-1640 had an enhancing eﬀect on parasite
growth (production of high levels of C. parvum developmental stages in
vitro), as did increasing FBS from 5% to 10% v/v in the media. Addi-
tional sugar supplements (glucose, maltose, galactose and mannose)
and insulin also had a positive eﬀect. The ﬁnal supplemented medium,
consisting of RPMI 1640 with 10% FBS, 15mM HEPES, 50mM glucose,
and 35mg of ascorbic acid, 1.0mg of folic acid, 4.0mg of 4-amino-
benzoic acid, 2.0mg of calcium pantothenate, 0.1 U of insulin, 100 U of
penicillin G, 100mg of streptomycin, and 0.25mg of amphotericin B
per ml (pH 7.4) supported a ten-fold increase in parasite abundance
compared to base RPMI-1640 (Upton et al., 1995). This medium is
commonly employed when culturing C. parvum, although another
medium formulation has been developed which can maintain HCT-
8 cells and parasitism for two weeks (Perez Cordon et al., 2007). This
formulation consists of RPMI-1640 medium with 10% FBS, pH 7.2 with
CaCl2 and MgCl2 at 1mM, and also requires that the cells (HCT-8) have
no medium renewal for a week prior to infection.
While long-term culture in a single culture vessel is impossible with
the HCT-8 cell line, Hijjawi et al. reported the culture of C. parvum in
HCT-8 cells for 25 days through sub-culturing (Hijjawi et al., 2001).
This was attributed to maintaining the pH of the culture medium be-
tween 7.2 and 7.6 by changing the culture medium every two to three
days. The success may also be attributed to HCT-8 monolayers up to 67
days old being capable of supporting infection (Sifuentes and Di
Giovanni George D., 2007). More recently, C. parvum infection was
maintained for 120 h using primary human intestinal epithelial cells,
which provided a signiﬁcantly longer infection time compared to 48 h
using HCT-8 cells (Castellanos-Gonzalez et al., 2013). Primary cells
provide advantages over cancer derived cell lines, such as retaining
tissue markers and morphology and are functionally closer to in vivo
models (Varughese et al., 2014). The disadvantage is their ﬁnite life-
span and the resulting need for a continued supply of these cells from
animal or human tissues. The morphology of host cells has not been
studied in great detail, however some cell lines, which support infection
have been reported as having microvillus like extensions (Current and
Long, 1983; Flanigan et al., 1991; Upton et al., 1994b). These exten-
sions may play an important role in parasite development, as the ob-
servations that microvillus proteins localise to the parasite attachment
site (Bonnin et al., 1999). Given the nature of encapsulation by the host
cell (Chen et al., 2003; Borowski et al., 2010), host cell morphology
may be worth investigating.
Recently, Miller et al. reported the successful propagation of C.
parvum in the oesophageal squamous cell carcinoma cell line COLO-
680N in RPMI-1640 medium supplemented with 10% FBS. COLO-680N
cells produced more oocysts and the infection could be maintained for
as long as two months without subculturing (Miller et al., 2018a). The
presented novel cell culture enables the sustainable, continuous pro-
pagation of infectious C. parvum oocysts and the systematic investiga-
tion of Cryptosporidium life cycle. Previously attempts to cultivate
Cryptosporidium in cell culture were aﬀected by a lack of oocyst pro-
duction or required sophisticated, expensive equipment and meth-
odologies to support 3D cultures (see below) that are not commonly
available to research laboratories (Yin et al., 2010; Karanis and
Aldeyarbi, 2011; Striepen, 2013; Muller and Hemphill, 2013; Morada
et al., 2016; Heo et al., 2018). The COLO-680N platform does not share
these shortcomings. The COLO-680N platform enabled C. parvum pro-
pagation, the sustainable production of C. parvum oocysts, and the in-
vestigation of the C. parvum biology at a laboratory scale in standard,
easy to use 2D tissue cultures with commonly available equipment and
particular expertise. Furthermore, their study demonstrated a long-term
maintenance of the cell-line and subsequently a prolonged production
of oocysts as well, in addition to a ﬁrst of its kind ability to cryo-
conserve the parasite for greater long-term storage or transportation,
systems both urgently needed by the ﬁeld (Striepen, 2013; Checkley
et al., 2015). The authors also presented for the ﬁrst time, a collection
of additional tools (lipidomics ﬁngerprinting and atomic force micro-
scopy) for investigating the intracellular cell biology and the oocyst
morphology and composition of Cryptosporidium, which can be in-
corporated in further studies to provide a better understanding of the
infection and life-cycle of the parasite (Miller et al., 2018a).
The need for long term and high yield production of oocysts has led
to an interest in 3D or organoid-type culturing systems and organoid
models. These systems allow for higher cell densities and subsequent
parasite yields, along with allowing long-term parasite propagation.
The 3D culture environment may also provide a more accurate model of
in vivo infection. Early eﬀorts to develop 3D cultures used HCT-8 cells in
a low shear microgravity environment, incubated with porcine small
intestinal grafts to promote diﬀerentiation into cuboidal epithelia and
brush border formation (Alcantara Warren et al., 2008). This method
allowed the intestinal epithelium to increase parasite numbers for 48 h.
However, the infection decreased after this time, accompanied by a
reduction in host cell attachment (Alcantara Warren et al., 2008). The
method provided a proof of concept, that bioreactor systems can be
used to produce C. parvum parasites, and with the additional medium
supplements, the system may be adapted as a productive culture
method. Following this, the culture of C. parvum was recently reported
using a hollow ﬁbre bioreactor system and maintained for over six
months (Morada et al., 2016). The system produced 1×108 oocysts per
day per mL of culture compared with reported 1×106 oocysts pro-
duced in traditional 2D culture vessels. Another recent report described
the culture of C. parvum in a model intestinal system developed using a
silk ﬁbre scaﬀold, which supported infection for two weeks (DeCicco
RePass Maria A. et al., 2017). While the method provides a good model
of in vivo cryptosporidiosis, the use of multiple cell lines including in-
testinal myoﬁbroblasts and the need for specialist equipment is a large
cost barrier for many labs. For long term Cryptosporidium culture, the
adoption of 3D culture technology by several labs will require a low-
cost methodology and simple protocol, which allows routine harvesting
of large numbers of oocysts. Even more recently two independent re-
ports have demonstrated propagation of Cryptosporidium along with
insights on host-parasite interactions in 3D culturing systems. In the
ﬁrst one, C. parvum was cultured for up to 27 days using a 3D culture of
adult murine colonic explants, while demonstrating new evidence of
potential role of the parasite in inducing carcinogenesis in the host
(Baydoun et al., 2017). In the second study, the authors demonstrated
the Cryptosporidium can infect epithelial organoids derived from human
small intestine and lung (Heo et al., 2018), while investigating the al-
terations of the parasite's transcriptome during invasion (see below in
‘omics session). These apparatuses provide a step forward in our un-
derstanding of the infection strategies of the parasite and production of
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oocysts in animal-free models, but they have their limitations in both
investigating the parasite's invasion in real time, but also in utilising
these in large-scale drug screening investigations.
Despite these advances, there has also been considerable interest in
propagating the parasite in the absence of host cells. This method would
oﬀer considerable advantages compared to host cell culture removing
the need to purify the parasite from host cell material. The ﬁrst report
of in vitro culture was by Hijjawi in 2004, who described the entire life
cycle of C. parvum in host cell free culture (Hijjawi et al., 2004). Uti-
lising a modiﬁed version of RPMI 1640 with supplements and coagu-
lated calf serum, the authors observed stages from inoculated spor-
ozoites through to sporulated oocysts, along with additional
extracellular stages. Previously, novel extracellular stages had been
puriﬁed from the guts of infected mice (Hijjawi et al., 2002). Un-
fortunately, the results observed were not readily reproducible by other
groups (Girouard et al., 2006; Woods and Upton, 2007). Woods and
Upton observed that the ﬁgures reported as being ‘extracellular gamont
like stages’ were more likely to be fungal contaminants (Woods and
Upton, 2007) given the similar morphology and the lack of antifungals
in the culture medium (Hijjawi et al., 2004). Previous reports (Karanis
et al., 2008) have demonstrated the capability of maintaining the
merozoite stages of Cryptosporidium, but the authors were not able to
further culture the parasite. As discussed earlier, two groups have de-
termined that alleged ‘merozoites’ were in fact aged sporozoites (Petry
et al., 2009; Matsubayashi et al., 2010). A recent study using the de-
scribed maintenance medium (Hijjawi et al., 2004) to culture C. parvum
showed stages using scanning electron microscopy (Yang et al., 2015).
Only stages from inoculated oocysts to type-I merozoites were de-
scribed, and there were no cases of either sexual stages or the pre-
viously described ‘extracellular gamont like stages (Hijjawi et al., 2004)
in culture. Lately, Aldeyarbi and Karanis described the complete life
cycle of C. parvum in the absence of host cells using cell free main-
tenance medium Express Five™ serum free medium (Aldeyarbi and
Karanis, 2016a, 2016b, 2016c).
In summary, cell-free culture has its appeals and needs to be in-
vestigated further as an alternative to current commercial animal
sources, but what is urgently needed is an accurate in vitro model of
infection. Currently, the COLO-680N platform can provide a robust 2D
culturing system, which allows a more in-depth examination of the
host-parasite relationship as well as a life-cycle wide examination of
parasite metabolic processes (Miller et al., 2018a). This culturing
platform will enable the investigation into the genetic, cellular, bio-
chemical, immunological and metabolomic alterations of Cryptospor-
idium and its host and to develop new drug screening platforms based
on this cell line. Using similar tactics (Miller et al., 2018a), future re-
search should also focus on exploring other potential cell systems that
could be used in addition to animal models or organoid-type culturing
to spearhead our understanding of the disease and the life cycle of
Cryptosporidium.
3. Cryptosporidium ‘omics and in vitro research
To understand the biology of the parasite, we survey the current
knowledge of in vitro Cryptosporidium ‘omics, focusing on gene expres-
sion proﬁle upon excystation and host infection and to which degree
these changes may inﬂuence the host and/or govern infectivity. It is
understood that upon infection, both host cells and parasites undergo
major remodelling in gene regulation such as the induction of factors
involved in the host immune response or the parasite invasion process,
respectively. However, it is clear that the dynamics of gene expression
extend beyond these pathways and this is why a great fraction of recent
studies have focused on identifying RNAs or proteins with altered ex-
pression during the infection process, by examining the status quo of
Cryptosporidium undergoing the excystation process and/or while in-
teracting with its host. For C. parvum, the implementation of tran-
scriptomics and proteomics studies has proven very challenging, due to
the diﬃculty of isolating intracellular stages of infection and the lack of
a gene engineering platform. However, recent advances, such as the
development of in vitro models (see section above) as well as the de-
velopment of novel gene-editing tools (Vinayak et al., 2015; Pawlowic
et al., 2017), hold great promises for this research ﬁeld.
Genomic sequence analysis yields much biological information and
allows to compare genome features of diﬀerent parasites. The ﬁrst
complete genome sequence came from a C. parvum isolate subtype IIa,
using automated capillary sequencing (Abrahamsen et al., 2004). The
sequence was later improved by next generation sequencing and the
revised annotation identiﬁed 3805 protein-coding genes (Isaza et al.,
2015). Further sequence comparison between the type II a isolate
(IOWA) and another subtype IId isolate from El Beheira Province,
Egypt, showed that signiﬁcant genomic diﬀerences could exist between
genomes from the same species and that biological diﬀerences between
isolates could be attributed to sequence polymorphism (Feng et al.,
2017). A collection of genomic and transciptomic data are currently
available in Cryptosporidium-dedicated database at the CryptoDB
(http://cryptodb.org/cryptodb/) (Heiges et al., 2006). These analyses
established that the C. parvum genome lacks apicoplast and mitochon-
drial genes and has fewer genes encoding metabolic function and var-
iant surface proteins compared to other apicomplexan parasites
(Abrahamsen et al., 2004). Notably, the C. parvum genome holds very
few introns (only 5% of genes have introns), and the parasite encodes
therefore few protein isoforms. Since then, additional Cryptosporidium
genomes (C. muris, C. andersonii and C. ubuiquitum) and strains have
been sequenced, showing genetic variation and composition in the
various species, and in extreme cases, further genetic streamline (Liu
et al., 2016).
To further understand the biology of the parasite, the use of pro-
teomics techniques is also important. Siddiki et al., for example, used
mass spectrometry based BLAST (MS BLAST) to identify C. parvum
proteins from frozen sporozoites pellets isolated from lamb faecal
samples. They separated the total proteins by 1D-SDS-PAGE and ana-
lysed 20 slices by 2D-n-LC MS/MS (Siddiki and Wastling, 2009). Ap-
plying this approach, the authors identiﬁed 84 Cryptosporidium-speciﬁc
proteins; a third being previously hypothetical and another third being
involved in protein biosynthesis. In another study, Snelling et al. also
used a mass spectrometry approach, but rather than solely analysing
the proteome of Cryptosporidium, they also tried to detect proteins
which exhibited diﬀerential expression in excysted sporozoites com-
pared to non-excysted sporozoites (Snelling et al., 2006). Their pro-
teomics’ analyses revealed the expression of 26 proteins, which were
signiﬁcantly induced following excystation, including ribosomal pro-
teins, metabolic enzymes and heat shock proteins. Interestingly, three
of the identiﬁed proteins were apicomplexan-speciﬁc and ﬁve were
Cryptosporidium-speciﬁc. As suggested by the authors, all identiﬁed
proteins could be involved in vital step of the pathogenesis. However, it
remains to determine whether the same response is elicited when
Cryptosporidium is actually in contact with the host or internalised.
Ultimately, it is the ﬂux of metabolites and the dynamics between
proteins from parasite and host, which govern their biological inter-
action, leading to the susceptibility or not of the host cell or organism.
The regulation of gene expression in C. parvum in relation with its host,
rather than in the process of excystation, has been the focus of many
studies. Some of these studies concentrated on the alterations of the
parasite as it follows its life cycle within the host, while others tried to
understand the interactions between the two organisms. Mauzy et al.,
carried out a large-scale expression analysis in vitro on 3281
Cryptosporidium genes using RT-PCR, looking at seven post-infection
time points from 2 to 72 h in HCT-8 cells (Mauzy et al., 2012). Their
work revealed numerous Cryptosporidium genes that share the same
pattern of expression. However, genes within a cluster did not map to
the same chromosomal location. Overall, they identiﬁed nine clusters,
which were associated with 18 categories of cellular processes, in-
cluding transcription, translation, and metabolism. This work suggests
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that the bulk of translation and turnover does not occur immediately
after anchorage of the parasite to the host cell, but in a later stage, when
the sporozoite has developed to trophozoites. Interestingly, genes pre-
sent in cluster six are mostly involved in transcription and RNA-asso-
ciated event (approximately 17%) as well as translation and protease
related processes (approximately 13%). This cluster exhibits a peak of
expression at 2 h’ post infection. Transcripts in cluster nine are involved
in translation (24%) and protease related processes (5%), but less so in
transcription and RNA-associated events (13%), and show a peak of
transcription at 6 h post infection. Oberstaller et al. took a diﬀerent
outlook on the Mauzy et al. study. They grouped the same genes ac-
cording to their pattern of expression, but used diﬀerent clustering
criteria to generate 200 clusters (Oberstaller et al., 2013). They then
searched for conserved and over-represented DNA motifs in the up-
stream promoter region of these genes and identiﬁed 25 DNA motifs,
which were further classiﬁed into 11 families. While some of these DNA
motifs are similar to the palindromic apicomplexan AP2 (ApiP2)
binding site, known as a transcriptional regulator (Mullapudi et al.,
2007; Yuda et al., 2010), many of the motifs are uncharacterised.
Though some are likely to modulate the outcome of infection by con-
trolling gene expression, it is hard to draw any conclusion at this stage.
To our knowledge there is no further study, which validates tran-
scription factors or proteins binding to these putative DNA motifs.
In another study by Wang et al., rather than measuring changes of
the full transcriptome, the authors examined the transcripts with very
low protein coding potential in infected epithelial cells. They showed
that this particular class of transcripts exhibited distinct gene expres-
sion patterns, at diﬀerent parasitic development stages, with some of
which are found at higher level in the sporozoites (Wang et al., 2017).
Many of the latter were discovered in the nuclear extract of infected
cells, possibly to modulate host cell gene expression. The implication of
these observations remains speculative, but shows that Cryptosporidium
has evolved a complex and diverse strategy to invade and control its
host.
While it is essential to identify changes in expression, knowing if
some of the co-regulated products interact or form complexes, give the
true picture of biological interaction (Reid and Berriman, 2013). Cur-
rently, we know next to nothing about which proteins interact between
parasites/host, since information retrieved from host-parasite protein-
protein interactions in Cryptosporidium-infected hosts is very limited. It
currently relies on speciﬁc sequence/protein conservations and there is
a need of a large-scale analysis looking not only at co-regulation be-
tween parasite and host, but also exploring the shaped microbiome and
metabolome. As thus, a combination of experimental infections in an-
imals and or organoids (see above) followed-up by a combination me-
tagenomics, transcriptomics (Heo et al., 2018) and metabolomics (using
mass spectrometry and/or 1H Nuclear Magnetic Resonance-based)
would allow a better understanding on the parasites’ interactions with
their hosts and determination of the factors that underlie the variable
clinical consequences of Cryptosporidium infection.
4. Cryptosporidium drug screening and potential treatments
While Cryptosporidium species are globally observed, they have the
most devastating eﬀect in less developed countries, and thus the current
strategy has been focused on drug repurposing (use of existing medi-
cations) rather than the development of rational drug design-a costly
tactic. To date, nitazoxanide is the only FDA approved treatment
against infection by Cryptosporidium. However, as highlighted pre-
viously, it remains ineﬃcient especially on immunocompromised pa-
tients such as HIV-positive patients. Therefore, the search for a drug
more appropriate for a large spectrum of patients goes on.
Compounds used versus many apicomplexan parasites are un-
suitable against Cryptosporidium infection, since the parasite lacks the
apicoplast organelle, the citrate cycle and the cytochrome-based re-
spiratory chain. Nonetheless, other metabolic pathways are still present
and could be used as potential drug targets. With this approach in mind,
Besoﬀ and co-authors screened the Medecines for Malaria Venture
(MMV) Open Access Malaria box, a collection of 400 compounds, by
measuring growth inhibition of Cryptosporidium within HCT-8 infected
cells (Bessoﬀ et al., 2014). The allopurinol scaﬀold (0.12 μM) and the
quinolinol scaﬀold (0.054 μM) showed the best activity against C.
parvum infection. Other studies have been restricted to speciﬁc groups
of compounds. For instance, studies have used the benzimidazole nu-
cleus, as it forms the core of many antiparasitic, antihelminthic, anti-
fungal and anti-inﬂammatory drugs. This observation prompted Grac-
zyk's group to examine the eﬀect of 11 benzimidazole derivatives on C.
parvum -infected HCT-8 cell using an immunoassay approach with rat
anti-Cryptosporidium polyclonal sera (Graczyk et al., 2011). Nine out of
11 benzimidazole compounds tested showed reduced volume of de-
velopmental stages of C. parvum in vitro. Nonetheless, the mechanisms
of inhibition were not clear and potential side-eﬀects to the host's liver
have been hinted at.
To step up the search for suitable treatments that beneﬁt all suf-
ferers, a more systematic approach is necessary. Thus, the ﬁeld has seen
the emergence of cell-based high-throughput assays designed to screen
large panel of existing drugs. For example, Bessoﬀ et al. performed a
high throughput screening, on C. parvum-infected HCT-8 cells, testing
the National institute of Health library of compounds, a collection of
723 FDA-approved drugs (Bessoﬀ et al., 2013). They identiﬁed pyr-
imidine analogues and statin drugs as promising anti-Cryptosporidium
compounds-showing over 80% inhibition of Cryptosporidium at below
10 μM concentration. Reﬁning their analysis using structure activity
relationship (SAR), they isolated itavastatin, an inhibitor of human 3-
hydroxy-3 methyl-glutaryl-coenzyne A reductase. In a parallel study,
Love et al. used a methodology modiﬁed from Bessof et al. (Bessoﬀ
et al., 2013) and screened 78,942 compounds to identify potential anti-
cryptosporidial drugs (Love et al., 2017). Their bioactive hits for C.
parvum were also counter-screened against C. hominis. While a few
potent compounds against Cryptosporidium were identiﬁed, this type of
phenotypic screen has limitations. It is diﬃcult to identify whether
observed eﬀects are due to inhibition of the host or inhibition of
Cryptosporidium activity. As a result, most of the drugs initially retained
after the screen, exhibited a limited therapeutic index. Clofazimine, on
the other hand, was taken forward and was further tested in a killing
activity assay (treatment of in vitro cell cultures, followed by compound
washout), which showed that the parasite growth was greatly reduced
(> 70–75%) at EC50 of 15 nM. More strikingly, single-dose treatment
on mice also eﬀectively reduced oocyst shedding. This study therefore
established Clofazimine as a potential repurposing candidate for the
treatment of cryptosporidiosis. Lastly, Manjunatha et al. screened 6220
compounds against C. parvum in an infection assay in HCT-8 and found
that imidazopyrzynes and pyrazolopyridines exhibited sub-micromolar
cellular activity against Cryptosporidium (Manjunatha et al., 2017). The
pyrazolopyridine KDU731 came up as a potential anti-cryptosporidial
drug candidate that is active against both C. parvum and C. hominis.
Additionally, unlike nitazoxanide, KDU731 demonstrated in vivo eﬃ-
cacy in immunocompromised mice.
Beside these large-scale studies, which are expensive and often re-
quire several replicates of screening, in silico approaches oﬀer the ad-
vantage that they predict structure and biological characteristics of
proteins. Shrivastava et al. for example, used CryptoDB database
(Heiges et al., 2006) to ﬁnd novel drug targets using the parasites
predicted proteome (Shrivastava et al., 2017). Roughly, 50% of proteins
in both C. hominis TU502 and C. parvum IOWA in the CryptoDB
database are hypothetical or unnamed. From these, 105 proteins that
were present in both species, were searched for their uniqueness via
BLAST analysis, with the reasoning these might be potential drug
target. Such approach revealed a unique hypothetical protein in C.
hominis genome TU502HP. The authors, however, did not describe the
nature of this uniqueness and simply states that it bears 91% sequence
identity with C. parvum (CryptoDB: cgd2_2550) with functional
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similarity with human transporting 3. A docking study reported N-(3-
chlorobenzyl)ethane-1,2-diamine as the best inhibitor in terms of
docking score and binding energy. In this instance, the approach,
however, is restricted to one Cryptosporidium species, namely C. ho-
minis, as it purposely selects for a unique trait/gene target. However,
while this in silico is innovative, the inhibitor/target interaction de-
scribed in this study remains to be validated experimentally. Because
Cryptosporidium spp interaction with its host(s) is complex, drug target
identiﬁcation requires in vitro and in vivo validation in order to identify
compounds suitable for follow-up testing. In vitro (cell lines) models
have to be considered in the context of drug absorption and metabo-
lism, in animals and humans and it therefore necessary to take a multi-
validation approach as in vitro and in vivomodels are likely to show only
partial functional overlap. For example, earlier work by Culshaw et al.,
have suggested that IFN-gamma protects against many protozoan
parasites including Cryptosporidium species (Culshaw et al., 1997).
Transgenic mice models (e.g. IFN-gamma R-KO) were shown to survive
gavage by large number of oocysts (2000 oocysts per animal) and
achieved high rate of ampliﬁcation (von Oettingen et al., 2008). In vitro
studies in cell cultures have also shown a direct inhibitory action of
IFN-gamma on C. parvum infected human enterocytes, but this was
dependent on the cell type (Caco-2 and HT-29, but not HT-4) and the
amount of time elapsed between infection and treatment with INF-
gamma. While in vivo studies highlight the role played by IFN-gamma in
C. parvum infection in mice (Lykens et al., 2010), the outcome is less
clear in human infections (Janssen et al., 2002). Taken together, this
shows that additional studies are essential to further deﬁne the role of
cytokines in the immune response to Cryptosporidium infection. For
example, the transgenic INF-gamma mouse model has been used in
combination with genetic manipulation of C. parvum (UGA1 strain)
(Vinayak et al., 2015; Pawlowic et al., 2017)to rank the safety and ef-
ﬁcacy of Bumper Kinase Inhibitors (BKIs) against C. parvum Calcium-
Dependent Protein Kinase (CDPK1), showing that BKI 1369 oﬀers po-
sitive prospects of future therapy for infected patients.
In summary, a lot of eﬀort has been invested in the search for new
treatment against cryptosporidiosis, which may see the emergence of
new drugs on the market. Currently, clofazimine and TU502HP in-
hibitors are both potential candidates, while clofazimine, as a re-
purposed-drug, may not need approval for new handlings. In parallel,
there is an urgent need for the development of high-throughput drug
screening platform for both C. parvum and C.hominis that will enable
both the identiﬁcation of anti-Cryptosporidium compounds but also
chemical biology approaches to elucidate Cryptosporidium biology. The
long-term cultivation culturing system (Miller et al., 2018a) along with
transfection (e.g. using the CRISPR/Cas9 system) protocols (Vinayak
et al., 2015) that will allow the visualisation of ﬂuorescent parasites
will enable monitoring Cryptosporidium replication and, hence identi-
ﬁcation of additional anti-parasitic drug candidates.
5. Future work
While substantial improvements have been made in understanding
Cryptosporidium parasites and their biology, much progress remains to
be made. Recent successes in the ﬁelds of long term culturing (Heo
et al., 2018; Miller et al., 2018a) along with the establishment of the
CRISPR/Cas9 technology (Vinayak et al., 2015) may facilitate a number
of these required developments that are urgently needed, especially in
the areas of drug treatment and vaccine development. The cell biology
of Cryptosporidium infection has been widely documented using various
microscopy techniques, however live cell imaging allowing progress to
be tracked in real time is still lacking. In addition, the molecular basis of
the life cycle changes has yet to be discerned. In the future, it may be
possible to routinely transfect Cryptosporidium and maintain it in a long-
term culturing platform (Miller et al., 2018a) to identify crucial func-
tional genes, their roles and possible drug and vaccine targets. In ad-
dition, while a great number of Cryptosporidium predicted proteins are
currently of unknown function, knockout studies and monitor Cryptos-
poridium physiology/behaviour during infection, may also provide
some insight into their function. Being able to maintain stable subtypes
of the parasite, consider interactions of the parasite and potential drugs
and to assess the relationships between genotype and pathogenicity, it
would be possible to develop eﬀective treatments and vaccines against
cryptosporidiosis.
Acknowledgments:
LJ was supported by a Bill and Melinda Gates Foundation grant
awarded to ADT and MM (OPP1160937). CNM was supported by a GTA
studentship from the School of Biosciences, University of Kent. ADT is
also supported by a BBSRC research grant (BB/M009971/1). We would
like to thank the reviewers for the constructive feedback on the
manuscript.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.exppara.2018.12.001.
References
Abrahamsen, M.S., Templeton, T.J., Enomoto, S., Abrahante, J.E., Zhu, G., Lancto, C.A.,
Deng, M., Liu, C., Widmer, G., Tzipori, S., Buck, G.A., Xu, P., Bankier, A.T., Dear,
P.H., Konfortov, B.A., Spriggs, H.F., Iyer, L., Anantharaman, V., Aravind, L., Kapur,
V., 2004. Complete genome sequence of the apicomplexan, Cryptosporidium parvum.
Science (New York, N.Y.) 304, 441–445.
Alcantara Warren, C., Destura, R.V., Sevilleja, J.E., Barroso, L.F., Carvalho, H., Barrett,
L.J., O'Brien, A.D., Guerrant, R.L., 2008. Detection of epithelial-cell injury, and
quantiﬁcation of infection, in the HCT-8 organoid model of cryptosporidiosis. J.
Infect. Dis. 198, 143–149.
Aldeyarbi, H.M., Karanis, P., 2016a. Electron microscopic observation of the early stages
of Cryptosporidium parvum asexual multiplication and development in in vitro axenic
culture. Eur. J. Protistol. 52, 36–44.
Aldeyarbi, H.M., Karanis, P., 2016b. The ﬁne structure of sexual stage development and
sporogony of Cryptosporidium parvum in cell-free culture. Parasitology 143, 749–761.
Aldeyarbi, H.M., Karanis, P., 2016c. The ultra-structural similarities between
Cryptosporidium parvum and the gregarines. J. Eukaryot. Microbiol. 63, 79–85.
Amadi, B., Mwiya, M., Musuku, J., Watuka, A., Sianongo, S., Ayoub, A., Kelly, P., 2002.
Eﬀect of nitazoxanide on morbidity and mortality in Zambian children with cryp-
tosporidiosis: a randomised controlled trial. Lancet (London, England) 360,
1375–1380.
Arrowood, M.J., 2002. In vitro cultivation of Cryptosporidium species. Clin. Microbiol.
Rev. 15, 390–400.
Barbee, S.L., Weber, D.J., Sobsey, M.D., Rutala, W.A., 1999. Inactivation of
Cryptosporidium parvum oocyst infectivity by disinfection and sterilization processes.
Gastrointest. Endosc. 49, 605–611.
Baydoun, M., Vanneste, S.B., Creusy, C., Guyot, K., Gantois, N., Chabe, M., Delaire, B.,
Mouray, A., Baydoun, A., Forzy, G., Chieux, V., Gosset, P., Senez, V., Viscogliosi, E.,
Follet, J., Certad, G., 2017. Three-dimensional (3D) culture of adult murine colon as
an in vitro model of cryptosporidiosis: proof of concept. Sci. Rep. 7 17288-017-
17304-2.
Bessoﬀ, K., Sateriale, A., Lee, K.K., Huston, C.D., 2013. Drug repurposing screen reveals
FDA-approved inhibitors of human HMG-CoA reductase and isoprenoid synthesis that
block Cryptosporidium parvum growth. Antimicrob. Agents Chemother. 57,
1804–1814.
Bessoﬀ, K., Spangenberg, T., Foderaro, J.E., Jumani, R.S., Ward, G.E., Huston, C.D., 2014.
Identiﬁcation of Cryptosporidium parvum active chemical series by Repurposing the
open access malaria box. Antimicrob. Agents Chemother. 58, 2731–2739.
Beyer, T.V., Svezhova, N.V., Sidorenko, N.V., Khokhlov, S.E., 2000. Cryptosporidium
parvum (Coccidia, apicomplexa): some new ultrastructural observations on its en-
dogenous development. Eur. J. Protistol. 36, 151–159.
Bonnin, A., Lapillonne, A., Petrella, T., Lopez, J., Chaponnier, C., Gabbiani, G., Robine, S.,
Dubremetz, J.F., 1999. Immunodetection of the microvillous cytoskeleton molecules
villin and ezrin in the parasitophorous vacuole wall of Cryptosporidium parvum
(Protozoa: apicomplexa). Eur. J. Cell Biol. 78, 794–801.
Borowski, H., Thompson, R.C., Armstrong, T., Clode, P.L., 2010. Morphological char-
acterization of Cryptosporidium parvum life-cycle stages in an in vitro model system.
Parasitology 137, 13–26.
Bushen, O.Y., Kohli, A., Pinkerton, R.C., Dupnik, K., Newman, R.D., Sears, C.L., Fayer, R.,
Lima, A.A., Guerrant, R.L., 2007. Heavy cryptosporidial infections in children in
northeast Brazil: comparison of Cryptosporidium hominis and Cryptosporidium parvum.
Trans. R. Soc. Trop. Med. Hyg. 101, 378–384.
Capet, C., Kapel, N., Huneau, J.F., Magne, D., Laikuen, R., Tricottet, V., Benhamou, Y.,
Tome, D., Gobert, J.G., 1999. Cryptosporidium parvum infection in suckling rats: im-
pairment of mucosal permeability and Na(+)-glucose cotransport. Exp. Parasitol. 91,
A.J. Bones et al. ([SHULPHQWDO3DUDVLWRORJ\²

119–125.
Castellanos-Gonzalez, A., Cabada, M.M., Nichols, J., Gomez, G., White Jr., A.C., 2013.
Human primary intestinal epithelial cells as an improved in vitro model for
Cryptosporidium parvum infection. Infect. Immun. 81, 1996–2001.
Castellanos-Gonzalez, A., Yancey, L.S., Wang, H., Pantenburg, B., Liscum, K.R., Lewis,
D.E., Clinton White Jr., A., 2008. Cryptosporidium infection of human intestinal epi-
thelial cells increases expression of osteoprotegerin: a novel mechanism for evasion of
host defenses. JID (J. Infect. Dis.) 197, 916–923.
Chappell, C.L., Okhuysen, P.C., Langer-Curry, R., Widmer, G., Akiyoshi, D.E., Tanriverdi,
S., Tzipori, S., 2006. Cryptosporidium hominis: experimental challenge of healthy
adults. Am. J. Trop. Med. Hyg. 75, 851–857.
Chappell, C.L., Okhuysen, P.C., Langer-Curry, R.C., Akiyoshi, D.E., Widmer, G., Tzipori,
S., 2011. Cryptosporidium meleagridis: infectivity in healthy adult volunteers. Am. J.
Trop. Med. Hyg. 85, 238–242.
Checkley, W., White Jr., A.C., Jaganath, D., Arrowood, M.J., Chalmers, R.M., Chen, X.M.,
Fayer, R., Griﬃths, J.K., Guerrant, R.L., Hedstrom, L., Huston, C.D., Kotloﬀ, K.L.,
Kang, G., Mead, J.R., Miller, M., Petri Jr., W.A., Priest, J.W., Roos, D.S., Striepen, B.,
Thompson, R.C., Ward, H.D., Van Voorhis, W.A., Xiao, L., Zhu, G., Houpt, E.R., 2015.
A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for
Cryptosporidium. Lancet Infect. Dis. 15, 85–94.
Chen, X.M., Huang, B.Q., Splinter, P.L., Cao, H., Zhu, G., McNiven, M.A., Larusso, N.F.,
2003. Cryptosporidium parvum invasion of biliary epithelia requires host cell tyrosine
phosphorylation of cortactin via c-Src. Gastroenterology 125, 216–228.
Chen, X.M., Levine, S.A., Tietz, P., Krueger, E., McNiven, M.A., Jeﬀerson, D.M., Mahle,
M., LaRusso, N.F., 1998. Cryptosporidium parvum is cytopathic for cultured human
biliary epithelia via an apoptotic mechanism. Hepatology 28, 906–913.
Clode, P.L., Koh, W.H., Thompson, R.C.A., 2015. Life without a host cell: what is
Cryptosporidium? Trends Parasitol. 31, 614–624.
Culshaw, R.J., Bancroft, G.J., McDonald, V., 1997. Gut intraepithelial lymphocytes induce
immunity against Cryptosporidium infection through a mechanism involving gamma
interferon production. Infect. Immun. 65, 3074–3079.
Current, W.L., Haynes, T.B., 1984. Complete development of Cryptosporidium in cell
culture. Science 224, 603–605.
Current, W.L., Long, P.L., 1983. Development of human and calf Cryptosporidium in
chicken embryos author ( s ): William L . Current and peter L . Long published by :
oxford university press. J. Infect. Dis. 148, 1108–1113.
DeCicco RePass Maria, A., Chen, Y., Lin, Y., Zhou, W., Kaplan, D.L., Warda, H.D., 2017.
Novel bioengineered three-dimensional human intestinal model for long-term in-
fection of Cryptosporidium parvum. Infect. Immun. 85.
DuPont, H.L., Chappell, C.L., Sterling, C.R., Okhuysen, P.C., Rose, J.B., Jakubowski, W.,
1995. The infectivity of Cryptosporidium parvum in healthy volunteers. N. Engl. J.
Med. 332, 855–859.
Edwinson, A., Widmer, G., McEvoy, J., 2016. Glycoproteins and Gal-GalNAc cause
Cryptosporidium to switch from an invasive sporozoite to a replicative trophozoite.
Int. J. Parasitol. 46, 67–74.
Elliott, D.A., Clark, D.P., 2000. Cryptosporidium parvum induces host cell actin accumu-
lation at the host-parasite interface. Infect. Immun. 68, 2315–2322.
Evans, D.F., Pye, G., Bramley, R., Clark, A.G., Dyson, T.J., Hardcastle, J.D., 1988.
Measurement of gastrointestinal pH proﬁles in normal ambulant human subjects. Gut
29, 1035–1041.
Fayer, R., Nerad, T., 1996. Eﬀects of low temperatures on viability of Cryptosporidium
parvum oocysts. Appl. Environ. Microbiol. 62, 1431–1433.
Fayer, R., Trout, J.M., Jenkins, M.C., 1998. Infectivity of Cryptosporidium parvum oocysts
stored in water at environmental temperatures. J. Parasitol. 84, 1165.
Fayer II., R., 1994. Eﬀect of high temperature on infectivity of Cryptosporidium parvum
oocysts in water. Appl. Environ. Microbiol. 60, 2732–2735.
Feng, Y., Li, N., Roellig, D.M., Kelley, A., Liu, G., Amer, S., Tang, K., Zhang, L., Xiao, L.,
2017. Comparative genomic analysis of the IId subtype family of Cryptosporidium
parvum. Int. J. Parasitol. 47, 281–290.
Flanigan, T.P., Aji, T., Marshall, R., Soave, R., Aikawa, M., Kaetzel, C., 1991. Asexual
development of Cryptosporidium parvum within a diﬀerentiated human enterocyte
cell-line. Infect. Immun. 59, 234–239.
Forney, J.R., Vaughan, D.K., Yang, S., Healey, M.C., 1998. Actin-dependent motility in
Cryptosporidium parvum sporozoites. J. Parasitol. 84, 908–913.
Fujino, T., Matsui, T., Kobayashi, F., Haruki, K., Yoshino, Y., Kajima, J., Tsuji, M., 2002.
The eﬀect of heating against Cryptosporidium oocysts. J. Vet. Med. Sci. 64, 199–200.
Girouard, D., Gallant, J., Akiyoshi, D.E., Nunnari, J., Tzipori, S., 2006. Failure to pro-
pagate Cryptosporidium spp. in cell-free culture. J. Parasitol. 92, 399–400.
Graczyk, Z., Chomicz, L., Kozlowska, M., Kazimierczuk, Z., Graczyk, T.K., 2011. Novel
and promising compounds to treat Cryptosporidium parvum infections. Parasitol. Res.
109, 591–594.
Harris, J.R., Petry, F., 1999. Cryptosporidium parvum: structural components of the oocyst
wall. J. Parasitol. 85, 839–849.
Heiges, M., Wang, H., Robinson, E., Aurrecoechea, C., Gao, X., Kaluskar, N., Rhodes, P.,
Wang, S., He, C.Z., Su, Y., Miller, J., Kraemer, E., Kissinger, J.C., 2006. CryptoDB: a
Cryptosporidium bioinformatics resource update. Nucleic Acids Res. 34, D419–D422.
Heo, I., Dutta, D., Schaefer, D.A., Iakobachvili, N., Artegiani, B., Sachs, N., Boonekamp,
K.E., Bowden, G., Hendrickx, A.P.A., Willems, R.J.L., Peters, P.J., Riggs, M.W.,
O'Connor, R., Clevers, H., 2018. Modelling Cryptosporidium infection in human small
intestinal and lung organoids. Nature microbiology 3, 814–823.
Hijjawi, N., 2010. Cryptosporidium: new developments in cell culture. Exp. Parasitol. 124,
54–60.
Hijjawi, N., Estcourt, A., Yang, R., Monis, P., Ryan, U., 2010. Complete development and
multiplication of Cryptosporidium hominis in cell-free culture. Vet. Parasitol. 169,
29–36.
Hijjawi, N.S., Meloni, B.P., Morgan, U.M., Thompson, R.C., 2001. Complete development
and long-term maintenance of Cryptosporidium parvum human and cattle genotypes in
cell culture. Int. J. Parasitol. 31, 1048–1055.
Hijjawi, N.S., Meloni, B.P., Ng'anzo, M., Ryan, U.M., Olson, M.E., Cox, P.T., Monis, P.T.,
Thompson, R.C., 2004. Complete development of Cryptosporidium parvum in host cell-
free culture. Int. J. Parasitol. 34, 769–777.
Hijjawi, N.S., Meloni, B.P., Ryan, U.M., Olson, M.E., Thompson, R.C., 2002. Successful in
vitro cultivation of Cryptosporidium andersoni: evidence for the existence of novel
extracellular stages in the life cycle and implications for the classiﬁcation of
Cryptosporidium. Int. J. Parasitol. 32, 1719–1726.
Hjort, K., Goldberg, A.V., Tsaousis, A.D., Hirt, R.P., Embley, T.M., 2010. Diversity and
reductive evolution of mitochondria among microbial eukaryotes. Philos. Trans. R.
Soc. Lond. Ser. B Biol. Sci. 365, 713–727.
Huang, B.Q., Chen, X., LaRusso, N.F., 2004. Cryptosporidium parvum attachment to and
internalization by human biliary epithelia in vitro: a morphologic study. J. Parasitol.
90, 212–221.
Isaza, J.P., Galvan, A.L., Polanco, V., Huang, B., Matveyev, A.V., Serrano, M.G., Manque,
P., Buck, G.A., Alzate, J.F., 2015. Revisiting the reference genomes of human pa-
thogenic Cryptosporidium species: reannotation of C. parvum Iowa and a new C. ho-
minis reference. Sci. Rep. 5, 16324.
Janssen, R., Van Wengen, A., Verhard, E., De Boer, T., Zomerdijk, T., Ottenhoﬀ, T.H., Van
Dissel, J.T., 2002. Divergent role for TNF-alpha in IFN-gamma-induced killing of
Toxoplasma gondii and Salmonella typhimurium contributes to selective susceptibility
of patients with partial IFN-gamma receptor 1 deﬁciency. Journal of immunology
(Baltimore, Md 169, 3900–3907 1950.
Jenkins, M.B., Eaglesham, B.S., Anthony, L.C., Kachlany, S.C., Bowman, D.D., Ghiorse,
W.C., 2010. Signiﬁcance of wall structure, macromolecular composition, and surface
polymers to the survival and transport of Cryptosporidium parvum oocysts. Appl.
Environ. Microbiol. 76, 1926–1934.
Johnson, A.M., Linden, K., Ciociola, K.M., De Leon, R., Widmer, G., Rochelle, P.A., 2005.
UV inactivation of Cryptosporidium hominis as measured in cell culture. Appl. Environ.
Microbiol. 71, 2800–2802.
Karanis, P., Aldeyarbi, H.M., 2011. Evolution of Cryptosporidium in vitro culture. Int. J.
Parasitol. 41, 1231–1242.
Karanis, P., Kimura, A., Nagasawa, H., Igarashi, I., Suzuki, N., 2008. Observations on
Cryptosporidium life cycle stages during excystation. J. Parasitol. 94, 298–300.
Karanis, P., 2017. The truth about in vitro culture of Cryptosporidium species. Parasitology
1–10.
Keithly, J.S., Langreth, S.G., Buttle, K.F., Mannella, C.A., 2005. Electron tomographic and
ultrastructural analysis of the Cryptosporidium parvum relict mitochondrion, its as-
sociated membranes, and organelles. J. Eukaryot. Microbiol. 52, 132–140.
Koh, W., Clode, P.L., Monis, P., Thompson, R.C.A., 2013. Multiplication of the waterborne
pathogen Cryptosporidium parvum in an aquatic bioﬁlm system. Parasites Vectors 6,
270.
Koh, W., Thompson, A., Edwards, H., Monis, P., Clode, P.L., 2014. Extracellular ex-
cystation and development of Cryptosporidium: tracing the fate of oocysts within
Pseudomonas aquatic bioﬁlm systems. BMC Microbiol. 14, 281.
Lingelbach, K., Joiner, K.A., 1998. The parasitophorous vacuole membrane surrounding
Plasmodium and Toxoplasma: an unusual compartment in infected cells. J. Cell Sci.
111 (Pt 11), 1467–1475.
Liu, S., Roellig, D.M., Guo, Y., Li, N., Frace, M.A., Tang, K., Zhang, L., Feng, Y., Xiao, L.,
2016. Evolution of mitosome metabolism and invasion-related proteins in
Cryptosporidium. BMC Genomics 17 1006-1016-3343-5.
Liu, Y., Kuhlenschmidt, M.S., Kuhlenschmidt, T.B., Nguyen, T.H., 2010. Composition and
conformation of Cryptosporidium parvum oocyst wall surface macromolecules and
their eﬀect on adhesion kinetics of oocysts on quartz surface. Biomacromolecules 11,
2109–2115.
Love, M.S., Beasley, F.C., Jumani, R.S., Wright, T.M., Chatterjee, A.K., Huston, C.D.,
Schultz, P.G., McNamara, C.W., 2017. A high-throughput phenotypic screen identi-
ﬁes clofazimine as a potential treatment for cryptosporidiosis. PLoS Neglected Trop.
Dis., e0005373.
Lykens, J.E., Terrell, C.E., Zoller, E.E., Divanovic, S., Trompette, A., Karp, C.L., Aliberti,
J., Flick, M.J., Jordan, M.B., 2010. Mice with a selective impairment of IFN-gamma
signaling in macrophage lineage cells demonstrate the critical role of IFN-gamma-
activated macrophages for the control of protozoan parasitic infections in vivo.
Journal of immunology (Baltimore, Md 184, 877–885 1950.
Manjunatha, U.H., Vinayak, S., Zambriski, J.A., Chao, A.T., Sy, T., Noble, C.G., Bonamy,
G.M.C., Kondreddi, R.R., Zou, B., Gedeck, P., Brooks, C.F., Herbert, G.T., Sateriale, A.,
Tandel, J., Noh, S., Lakshminarayana, S.B., Lim, S.H., Goodman, L.B., Bodenreider,
C., Feng, G., Zhang, L., Blasco, F., Wagner, J., Leong, F.J., Striepen, B., Diagana, T.T.,
2017. A Cryptosporidium PI(4)K inhibitor is a drug candidate for cryptosporidiosis.
Nature 546, 376–380.
Martinez, F., Mascaro, C., Rosales, M.J., Diaz, J., Cifuentes, J., Osuna, A., 1992. In vitro
multiplication of Cryptosporidium parvum in mouse peritoneal macrophages. Vet.
Parasitol. 42, 27–31.
Matsubayashi, M., Ando, H., Kimata, I., Nakagawa, H., Furuya, M., Tani, H., Sasai, K.,
2010. Morphological changes and viability of Cryptosporidium parvum sporozoites
after excystation in cell-free culture media. Parasitology 137, 1861–1866.
Matsuura, Y., Matsubayashi, M., Nukata, S., Shibahara, T., Ayukawa, O., Kondo, Y.,
Matsuo, T., Uni, S., Furuya, M., Tani, H., Tsuji, N., Sasai, K., 2017. Report of Fatal
Mixed Infection with Cryptosporidium parvum and Giardia intestinalis in Neonatal
Calves, vol. 62. pp. 214–220.
Mauzy, M.J., Enomoto, S., Lancto, C.A., Abrahamsen, M.S., Rutherford, M.S., 2012. The
Cryptosporidium parvum transcriptome during in vitro development. PloS One 7,
e31715.
Miller, C.N., Josse, L., Brown, I., Blakeman, B., Povey, J., Yiangou, L., Price, M., Cinatl,
J.J., Xue, W.F., Michaelis, M., Tsaousis, A.D., 2018a. A cell culture platform for
A.J. Bones et al. ([SHULPHQWDO3DUDVLWRORJ\²

Cryptosporidium that enables long-term cultivation and new tools for the systematic
investigation of its biology. Int. J. Parasitol. 48, 197–201.
Miller, C.N., Josse, L., Tsaousis, A.D., 2018b. Localization of Fe-S biosynthesis machinery
in Cryptosporidium parvum mitosome. J. Eukaryot. Microbiol. 65 (6), 913–922 Nov.
Morada, M., Lee, S., Gunther-Cummins, L., Weiss, L.M., Widmer, G., Tzipori, S., Yarlett,
N., 2016. Continuous culture of Cryptosporidium parvum using hollow ﬁber tech-
nology. Int. J. Parasitol. 46, 21–29.
Mullapudi, N., Lancto, C.A., Abrahamsen, M.S., Kissinger, J.C., 2007. Identiﬁcation of
putative cis-regulatory elements in Cryptosporidium parvum by de novo pattern
ﬁnding. BMC Genomics 8 13-2164-8-13.
Muller, J., Hemphill, A., 2013. In vitro culture systems for the study of apicomplexan
parasites in farm animals. Int. J. Parasitol. 43, 115–124.
Navin, T.R., Hardy, A.M., 1987. Cryptosporidiosis in patients with AIDS. J. Infect. Dis.
155, 150.
Nime, F.A., Burek, J.D., Page, D.L., Holscher, M.A., Yardley, J.H., 1976. Acute en-
terocolitis in a human being infected with the protozoan Cryptosporidium.
Gastroenterology 70, 592–598.
Noordeen, F., Horadagoda, N.U., Faizal, A.C., Rajapakse, R.P., Razak, M.A., Arulkanthan,
A., 2002. Infectivity of Cryptosporidium parvum isolated from asymptomatic adult
goats to mice and goat kids. Vet. Parasitol. 103, 217–225.
Oberstaller, J., Joseph, S.J., Kissinger, J.C., 2013. Genome-wide upstream motif analysis
of Cryptosporidium parvum genes clustered by expression proﬁle. BMC Genomics 14
516-2164-14-516.
O'Hara, S.P., Chen, X.M., 2011. The cell biology of Cryptosporidium infection. Microb.
Infect. 13, 721–730.
Pawlowic, M.C., Vinayak, S., Sateriale, A., Brooks, C.F., Striepen, B., 2017. Generating
and maintaining transgenic Cryptosporidium parvum parasites. Current protocols in
microbiology 46 20B.2.1-20B.2.32.
Pecková, R., Stuart, P.D., Sak, B., Květoňová, D., Kváč, M., Foitová, I., 2016. Statistical
comparison of excystation methods in Cryptosporidium parvum oocysts. Vet.
Parasitol 230, 1–5.
Perez Cordon, G., Marin, C., Romero, D., Rosales, C., Sanchez Moreno, M., Rosales, M.J.,
2007. More productive in vitro culture of Cryptosporidium parvum for better study of
the intra- and extracellular phases. Mem. Inst. Oswaldo Cruz 102, 567–571.
Perkins, M.E., Riojas, Y.A., Wu, T.W., Le Blancq, S.M., 1999. CpABC, a Cryptosporidium
parvum ATP-binding cassette protein at the host-parasite boundary in intracellular
stages. Proc. Natl. Acad. Sci. U.S.A. 96, 5734–5739.
Petry, F., Kneib, I., Harris, J.R., 2009. Morphology and in vitro infectivity of sporozoites
of Cryptosporidium parvum. J. Parasitol. 95, 1243–1246.
Petry, F., 2004. Microscopy microanalysis structural analysis of Cryptosporidium parvum.
In Vitro 586–601.
Pozio, E., Rezza, G., Boschini, A., Pezzotti, P., Tamburrini, A., Rossi, P., Di Fine, M.,
Smacchia, C., Schiesari, A., Gattei, E., Zucconi, R., Ballarini, P., 1997. Clinical
cryptosporidiosis and human immunodeﬁciency virus (HIV)-induced im-
munosuppression: ﬁndings from a longitudinal study of HIV-positive and HIV-nega-
tive former injection drug users. J. Infect. Dis. 176, 969–975.
Reduker, D.W., Speer, C.a., Blixt, J.a., 1985a. Ultrastructure of Cryptosporidium parvum
oocysts and excysting sporozoites as revealed by high resolution scanning electron
microscopy. J. Protozool. 32, 708–711.
Reduker, D., Speer, C., Blixt, J., 1985b. Ultrastructural changes in the oocyst wall during
excystation of Cryptosporidium parvum (Apicomplexa; Eucoccidiorida). Can. J. Zool.
63, 1892–1896.
Reid, A.J., Berriman, M., 2013. Genes involved in host-parasite interactions can be re-
vealed by their correlated expression. Nucleic Acids Res. 41, 1508–1518.
Richardson, E., Zerr, K., Tsaousis, A., Dorrell, R.G., Dacks, J.B., 2015. Evolutionary cell
biology: functional insight from "endless forms most beautiful". Mol. Biol. Cell 26,
4532–4538.
Riordan, C.E., Ault, J.G., Langreth, S.G., Keithly, J.S., 2003. Cryptosporidium parvum
Cpn60 targets a relict organelle. Curr. Genet. 44, 138–147.
Rosales, M.J., Cifuentes, J., Mascaro, C., 1993. Cryptosporidium parvum: culture in MDCK
cells. Exp. Parasitol. 76, 209–212.
Rossignol, J.F., Ayoub, A., Ayers, M.S., 2001. Treatment of diarrhea caused by
Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled
study of Nitazoxanide. J. Infect. Dis. 184, 103–106.
Ryan, U., Paparini, A., Monis, P., Hijjawi, N., 2016. It's oﬃcial - Cryptosporidium is a
gregarine: what are the implications for the water industry? Water Res. 105,
305–313.
Ryan, U., Hijjawi, N., 2015. New developments in Cryptosporidium research. Int. J.
Parasitol. 45, 367–373.
Shrivastava, A.K., Kumar, S., Sahu, P.S., Mahapatra, R.K., 2017. In silico identiﬁcation
and validation of a novel hypothetical protein in Cryptosporidium hominis and virtual
screening of inhibitors as therapeutics. Parasitol. Res. 116, 1533–1544.
Siddiki, A.M., Wastling, J.M., 2009. Charting the proteome of Cryptosporidium parvum
sporozoites using sequence similarity-based BLAST searching. J. Vet. Sci. 10,
203–210.
Sifuentes, L.Y., Di Giovanni George, D., 2007. Aged HCT-8 cell monolayers support
Cryptosporidium parvum infection. Appl. Environ. Microbiol. 73, 7548–7551.
Slifko, T.R., Friedman, D., Rose, J.B., Jakubowski, W., 1997. An in vitro method for de-
tecting infectious Cryptosporidium oocysts with cell culture. Appl. Environ. Microbiol.
63, 3669–3675.
Snelling, W.J., Lin, Q., Moore, J.E., Millar, B.C., Tosini, F., Pozio, E., Dooley, J.S.G.,
Lowery, C.J., 2006. Proteomics analysis and protein expression during sporozoite
excystation of Cryptosporidium parvum (Coccidia, apicomplexa). Molecular & Cellular
Proteomics 6, 346–355.
Striepen, B., 2013. Parasitic infections: time to tackle cryptosporidiosis. Nature 503,
189–191.
Thompson, R.C., Olson, M.E., Zhu, G., Enomoto, S., Abrahamsen, M.S., Hijjawi, N.S.,
2005. Cryptosporidium and cryptosporidiosis. Advances in Parasitology 59, 77–158.
Tumwine, J.K., Kekitiinwa, A., Nabukeera, N., Akiyoshi, D.E., Rich, S.M., Widmer, G.,
Feng, X., Tzipori, S., 2003. Cryptosporidium parvum in children with diarrhea in
mulago hospital, Kampala, Uganda. American Journal of Tropical Medicine and
Hygiene 68, 710–715.
Uga, S., Matsuo, J., Kono, E., Kimura, K., Inoue, M., Rai, S.K., Ono, K., 2000. Prevalence of
Cryptosporidium parvum infection and pattern of oocyst shedding in calves in Japan.
Veterinary parasitology 94, 27–32.
Umemiya, R., Fukuda, M., Fujisaki, K., Matsui, T., 2005. Electron microscopic observation
of the invasion process of Cryptosporidium parvum in severe combined im-
munodeﬁciency mice. The Journal of parasitology 91, 1034–1039.
Upton, S.J., Tilley, M., Brillhart, D.B., 1995. Eﬀects of select medium supplements on in-
vitro development of Cryptosporidium parvum in hct-8 cells. Journal of clinical mi-
crobiology 33, 371–375.
Upton, S.J., Tilley, M., Brillhart, D.B., 1994a. Comparative development of
Cryptosporidium parvum (Apicomplexa) in 11 continuous host cell lines. FEMS mi-
crobiology letters 118, 233–236.
Upton, S.J., Tilley, M., Nesterenko, M.V., Brillhart, D.B., 1994b. A simple and reliable
method of producing in vitro infections of Cryptosporidium parvum (Apicomplexa).
FEMS microbiology letters 118, 45–49.
Valigurova, A., Jirku, M., Koudela, B., Gelnar, M., Modry, D., Slapeta, J., 2008.
Cryptosporidia: epicellular parasites embraced by the host cell membrane.
International journal for parasitology 38, 913–922.
Varughese, E.A., Bennett-Stamper, C.L., Wymer, L.J., Yadav, J.S., 2014. A new in vitro
model using small intestinal epithelial cells to enhance infection of Cryptosporidium
parvum. Journal of microbiological methods 106, 47–54.
Villacorta, I., De Graaf, Dirk, Charlier, G., Peeters, J.E., 1996. Complete development of
Cryptosporidium parvum in MDBK cells. FEMS microbiology letters 142, 129–132.
Vinayak, S., Pawlowic, M.C., Sateriale, A., Brooks, C.F., Studstill, C.J., Bar-Peled, Y.,
Cipriano, M.J., Striepen, B., 2015. Genetic modiﬁcation of the diarrhoeal pathogen
Cryptosporidium parvum. Nature 523, 477–480.
von Oettingen, J., Nath-Chowdhury, M., Ward, B.J., Rodloﬀ, A.C., Arrowood, M.J., Ndao,
M., 2008. High-yield ampliﬁcation of Cryptosporidium parvum in interferon gamma
receptor knockout mice. Parasitology 135, 1151–1156.
Wang, Y., Gong, A.Y., Ma, S., Chen, X., Strauss-Soukup, J.K., Chen, X.M., 2017. Delivery
of parasite Cdg7_Flc_0990 RNA transcript into intestinal epithelial cells during
Cryptosporidium parvum infection suppresses host cell gene transcription through
epigenetic mechanisms. Cellular microbiology 19 10.1111/cmi.12760. Epub 2017
Jul 14.
Weisburger, W.R., Hutcheon, D.F., Yardley, J.H., Roche, J.C., Hillis, W.D., Charache, P.,
1979. Cryptosporidiosis in an immunosuppressed renal-transplant recipient with IgA
deﬁciency. American Journal of Clinical Pathology 72, 473–478.
Wetzel, D.M., Schmidt, J., Kuhlenschmidt, M.S., Dubey, J.P., Sibley, L.D., 2005. Gliding
motility leads to active cellular invasion by Cryptosporidium parvum sporozoites.
Infection and immunity 73, 5379–5387.
Woods, K.M., Upton, S.J., 2007. In vitro development of Cryptosporidium parvum in serum-
free media. Letters in applied microbiology 44, 520–523.
Yang, R., Elankumaran, Y., Hijjawi, N., Ryan, U., 2015. Validation of cell-free culture
using scanning electron microscopy (SEM) and gene expression studies. Experimental
parasitology 153, 55–62.
Yin, J.H., Shen, Y.J., Cao, J.P., 2010. Progress on the application of Cryptosporidium in-
fected animal models and in vitro cultivation. Zhongguo ji sheng chong xue yu ji
sheng chong bing za zhi = Chin. J. Parasitol. Parasit. Dis. 28, 387–392.
Yuda, M., Iwanaga, S., Shigenobu, S., Kato, T., Kaneko, I., 2010. Transcription factor AP2-
Sp and its target genes in malarial sporozoites. Molecular microbiology 75, 854–863.
Zapata, F., Perkins, M.E., Riojas, Y.a., Wu, T.W., Le Blancq Sylvie, M., 2002. The
Cryptosporidium parvum ABC protein family. Molecular and biochemical para-
sitology 120, 157–161.
Zhang, H., Guo, F., Zhu, G., 2012. Involvement of host cell integrin in Cryptosporidium
parvum infection. Infection and immunity 80, 1753–1758.
A.J. Bones et al. ([SHULPHQWDO3DUDVLWRORJ\²

